Recent Updates
Recently added Catalysts
NPCE Positive Sentiment

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Tuesday, August 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: NeuroPace, Inc. reported its financial results for the second quarter of 2026, highlighting a total revenue of $22.8 million, which includes $22.5 million from the RNS System, marking a 21.3% increase from the same period in 2025. The company also raised its revenue guidance for the year, indicating positive growth prospects.
Price reaction · baseline $15.05 (2026-08-11 close) · hit after-hours · clean, no other NPCE news in the window
day 0 close
-3.3%
day 1
-3.6%
day 3
-5.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Total revenue reached $22.8 million, showing strong growth.
  • RNS System revenue increased by 21.3% compared to the previous year.
  • The company raised its revenue guidance for 2026.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~38 mo
Minimal dilution risk
Lead asset
RNS System
Phase 2 · Epilepsy

Full Press Release Details

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. Second Quarter 2026 Financial Highlights Total revenue of $22.8 million in the second quarter of 2026 RNS System revenue of $22.5 million in the quarter, representing 21.3% growth compared to the second quarter of 2025 Net los

Frequently Asked Questions

What were NeuroPace's total revenues for Q2 2026?

NeuroPace reported total revenues of $22.8 million for Q2 2026.

How much did RNS System revenue grow in Q2 2026?

RNS System revenue grew by 21.3% compared to Q2 2025.

Did NeuroPace raise its revenue guidance for 2026?

Yes, NeuroPace raised its revenue guidance for the year 2026.

ShareAdd on Google
Tags: NPCE NeuroPace financial results revenue guidance epilepsy
Last updated: Aug 11, 2026

Biotech snapshot

Cash runway
$52M liquidity · $1M/mo burn
~38 mo
Minimal dilution risk
Lead asset
RNS SystemPhase 2
Epilepsy →